SG10201705285SA - Antisense oligonucleotides - Google Patents

Antisense oligonucleotides

Info

Publication number
SG10201705285SA
SG10201705285SA SG10201705285SA SG10201705285SA SG10201705285SA SG 10201705285S A SG10201705285S A SG 10201705285SA SG 10201705285S A SG10201705285S A SG 10201705285SA SG 10201705285S A SG10201705285S A SG 10201705285SA SG 10201705285S A SG10201705285S A SG 10201705285SA
Authority
SG
Singapore
Prior art keywords
antisense oligonucleotides
present
relates
antisense
modulates
Prior art date
Application number
SG10201705285SA
Inventor
Guccione Ernest
Wee Keng Boon Dave
Bertoletti Antonio
Original Assignee
Agency Science Tech & Res
Lion Tcr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Lion Tcr filed Critical Agency Science Tech & Res
Priority to SG10201705285SA priority Critical patent/SG10201705285SA/en
Priority to CA3066035A priority patent/CA3066035A1/en
Priority to KR1020207000349A priority patent/KR20200035937A/en
Priority to CN201880043866.7A priority patent/CN111630167A/en
Priority to US16/626,395 priority patent/US20200377883A1/en
Priority to SG11201911704UA priority patent/SG11201911704UA/en
Priority to EP18823314.2A priority patent/EP3645724A4/en
Priority to AU2018291556A priority patent/AU2018291556B2/en
Priority to JP2019572710A priority patent/JP7284718B2/en
Priority to PCT/SG2018/050313 priority patent/WO2019004939A1/en
Publication of SG10201705285SA publication Critical patent/SG10201705285SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

ANTISENSE OLIGONUCLEOTIDES The present invention relates to antisense oligonucleotides. In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. In an aspect of the present invention, there is provided an antisense oligonucleotide that modulates the function of a T-cell. (no suitable figure)
SG10201705285SA 2017-06-27 2017-06-27 Antisense oligonucleotides SG10201705285SA (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SG10201705285SA SG10201705285SA (en) 2017-06-27 2017-06-27 Antisense oligonucleotides
CA3066035A CA3066035A1 (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a t cell
KR1020207000349A KR20200035937A (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for regulating T cell function
CN201880043866.7A CN111630167A (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating T cell function
US16/626,395 US20200377883A1 (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a t cell
SG11201911704UA SG11201911704UA (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a t cell
EP18823314.2A EP3645724A4 (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a t cell
AU2018291556A AU2018291556B2 (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a T cell
JP2019572710A JP7284718B2 (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating T cell function
PCT/SG2018/050313 WO2019004939A1 (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a t cell

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201705285SA SG10201705285SA (en) 2017-06-27 2017-06-27 Antisense oligonucleotides

Publications (1)

Publication Number Publication Date
SG10201705285SA true SG10201705285SA (en) 2019-01-30

Family

ID=64742433

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201705285SA SG10201705285SA (en) 2017-06-27 2017-06-27 Antisense oligonucleotides
SG11201911704UA SG11201911704UA (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a t cell

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201911704UA SG11201911704UA (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a t cell

Country Status (9)

Country Link
US (1) US20200377883A1 (en)
EP (1) EP3645724A4 (en)
JP (1) JP7284718B2 (en)
KR (1) KR20200035937A (en)
CN (1) CN111630167A (en)
AU (1) AU2018291556B2 (en)
CA (1) CA3066035A1 (en)
SG (2) SG10201705285SA (en)
WO (1) WO2019004939A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109477073B (en) * 2016-03-31 2024-04-12 来恩生物医药私人有限公司 Non-activated T cells expressing exogenous virus specific T Cell Receptors (TCRs)
WO2020081764A1 (en) * 2018-10-18 2020-04-23 Synerk Inc. Compositions and methods for inhibiting tigit gene expression
EP3947678A1 (en) 2019-04-02 2022-02-09 ProQR Therapeutics II B.V. Antisense oligonucleotides for immunotherapy
CN109988842B (en) * 2019-04-19 2022-12-06 上海吉玛制药技术有限公司 Reagent group for in-situ detection of PDL1 by oligonucleotide labeled probe and application thereof
JP2022532998A (en) * 2019-04-26 2022-07-21 ストーク セラピューティクス，インク． Methods and Compositions for Modulating Selective Intron Splicing
CN110157705B (en) * 2019-05-16 2021-06-18 苏州安天圣施医药科技有限公司 Antisense oligonucleotide for inhibiting PD-1 signal at PDCD1 gene expression splicing level and screening method and application thereof
JP7337373B2 (en) * 2019-07-29 2023-09-04 サイアス株式会社 Method for producing antigen-specific T cells
AU2020405049A1 (en) * 2019-12-17 2022-06-23 The General Hospital Corporation Engineered immune cells with reduced toxicity and uses thereof
WO2021173812A1 (en) * 2020-02-28 2021-09-02 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
IL297686A (en) * 2020-04-30 2022-12-01 Secarna Pharmaceuticals Gmbh & Co Kg Pd-1-specific antisense oligonucleotide and its use in therapy
EP4211241A1 (en) * 2020-09-10 2023-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of splice switching oligonucleotides for exon skipping-mediated knockdown of nf-kb components in b cells
CN116615207A (en) * 2020-10-20 2023-08-18 伊姆诺私人投资有限公司 Modified immune cells
EP4267734A1 (en) 2020-12-22 2023-11-01 F. Hoffmann-La Roche AG Oligonucleotides targeting xbp1
WO2023073709A1 (en) * 2021-10-27 2023-05-04 Hadasit Medical Research Services & Development Ltd. Nucleic acid agents modulating pd-1 isoforms

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566132B1 (en) * 2001-04-26 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Interferon gamma receptor 1 expression
US8501704B2 (en) * 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
US20070111962A1 (en) * 2005-11-08 2007-05-17 Mourich Dan V Immunosuppression compound and treatment method
DK2735568T3 (en) * 2006-05-10 2017-11-13 Sarepta Therapeutics Inc OLIGONUCLEOTIDE ANALYSIS WITH CATIONIC BINDINGS BETWEEN SUB-UNITS
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
WO2011120101A1 (en) * 2010-04-01 2011-10-06 The University Of Queensland Small rna molecules and methods of use
WO2013135830A1 (en) * 2012-03-14 2013-09-19 Ruprecht-Karls-Universität Heidelberg Epigenetic signatures as marker for cardiomyopathies and myocardial insufficiencies
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
WO2014078749A1 (en) * 2012-11-15 2014-05-22 The Regents Of The University Of California Splice modulating oligonucleotides that inhibit cancer
EP2931893A1 (en) * 2012-12-13 2015-10-21 Universität Leipzig T-cell modulation by exon skipping
CN103820454B (en) * 2014-03-04 2016-03-30 上海金卫生物技术有限公司 The method of CRISPR-Cas9 specific knockdown people PD1 gene and the sgRNA for selectively targeted PD1 gene
SG10201809157VA (en) * 2014-04-18 2018-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2016138278A2 (en) * 2015-02-27 2016-09-01 Idera Pharmaceuticals, Inc. Compositions for inhibiting checkpoint gene expression and uses thereof
CN107847524A (en) * 2015-03-27 2018-03-27 哈佛学院校长同事会 By the T cell and its preparation and application of modification
MA43344A (en) * 2015-05-29 2018-04-11 Juno Therapeutics Inc COMPOSITION AND PROCEDURES FOR REGULATING INHIBITORING INTERACTIONS IN GENETICALLY MODIFIED CELLS
EP3384027A1 (en) * 2015-12-04 2018-10-10 Novartis AG Compositions and methods for immunooncology

Also Published As

Publication number Publication date
AU2018291556A1 (en) 2020-01-02
EP3645724A4 (en) 2021-07-21
KR20200035937A (en) 2020-04-06
JP7284718B2 (en) 2023-05-31
JP2020530981A (en) 2020-11-05
EP3645724A1 (en) 2020-05-06
WO2019004939A1 (en) 2019-01-03
AU2018291556B2 (en) 2021-12-09
SG11201911704UA (en) 2020-01-30
CN111630167A (en) 2020-09-04
US20200377883A1 (en) 2020-12-03
CA3066035A1 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
SG10201705285SA (en) Antisense oligonucleotides
MX2020004698A (en) Exosomes comprising rna therapeutics.
IL268422A (en) Targeted oligonucleotides
WO2019079402A3 (en) Improved delivery systems for moieties including cbd enhanced combinations, formulations and chimeras
PH12016501761A1 (en) Antisense nucleic acids
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
EA201892467A1 (en) Oligonucleotide Analogues Aimed at Human LMna
MX2020012133A (en) Complex containing oligonucleotide having immunopotentiating activity and use thereof.
PH12018500568A1 (en) Antisense nucleic acid
MX2019006879A (en) Exon skipping oligomer conjugates for muscular dystrophy.
MX2016016526A (en) Antisense nucleic acid.
SG11202005860SA (en) Amplifying, generating, or certifying randomness
IL272838A (en) Inhibiting ubiquitin specific peptidase 30
GB201711809D0 (en) Antisense oligonucleotide
IL288956A (en) Rna construct
EA201991450A1 (en) OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
MX2015015564A (en) Oligonucleotide modulators of b-cell cll/lymphoma 11a (bcl11a) and uses thereof.
MX2018002665A (en) Combination comprising immunostimulatory oligonucleotides.
MX2018016052A (en) Exon skipping oligomers for muscular dystrophy.
MX2020005754A (en) Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage.
EP3584319A4 (en) Single-stranded oligonucleotide
MX2018002998A (en) Nucleic acid derivative having immunostimulatory activity.
EP3660153A4 (en) Single-stranded oligonucleotide
EP3532617A4 (en) Antisense oligonucleotides
MX2017001369A (en) Rhodium alloys.